BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 23460711)

  • 1. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.
    Aparicio T; Jouve JL; Teillet L; Gargot D; Subtil F; Le Brun-Ly V; Cretin J; Locher C; Bouché O; Breysacher G; Charneau J; Seitz JF; Gasmi M; Stefani L; Ramdani M; Lecomte T; Mitry E
    J Clin Oncol; 2013 Apr; 31(11):1464-70. PubMed ID: 23460711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
    Aparicio T; Gargot D; Teillet L; Maillard E; Genet D; Cretin J; Locher C; Bouché O; Breysacher G; Seitz JF; Gasmi M; Stefani L; Ramdani M; Lecomte T; Auby D; Faroux R; Bachet JB; Lepère C; Khemissa F; Sobhani I; Boulat O; Mitry E; Jouve JL;
    Eur J Cancer; 2017 Mar; 74():98-108. PubMed ID: 27825697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
    Sastre J; Marcuello E; Masutti B; Navarro M; Gil S; Antón A; Abad A; Aranda E; Maurel J; Valladares M; Maestu I; Carrato A; Vicent JM; Díaz-Rubio E;
    J Clin Oncol; 2005 May; 23(15):3545-51. PubMed ID: 15908665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).
    Aparicio T; Lavau-Denes S; Phelip JM; Maillard E; Jouve JL; Gargot D; Gasmi M; Locher C; Adhoute X; Michel P; Khemissa F; Lecomte T; Provençal J; Breysacher G; Legoux JL; Lepère C; Charneau J; Cretin J; Chone L; Azzedine A; Bouché O; Sobhani I; Bedenne L; Mitry E;
    Ann Oncol; 2016 Jan; 27(1):121-7. PubMed ID: 26487578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
    Hamaker ME; Seynaeve C; Wymenga AN; van Tinteren H; Nortier JW; Maartense E; de Graaf H; de Jongh FE; Braun JJ; Los M; Schrama JG; van Leeuwen-Stok AE; de Groot SM; Smorenburg CH
    Breast; 2014 Feb; 23(1):81-7. PubMed ID: 24314824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
    Boige V; Mendiboure J; Pignon JP; Loriot MA; Castaing M; Barrois M; Malka D; Trégouët DA; Bouché O; Le Corre D; Miran I; Mulot C; Ducreux M; Beaune P; Laurent-Puig P
    J Clin Oncol; 2010 May; 28(15):2556-64. PubMed ID: 20385995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
    Carrato A; Swieboda-Sadlej A; Staszewska-Skurczynska M; Lim R; Roman L; Shparyk Y; Bondarenko I; Jonker DJ; Sun Y; De la Cruz JA; Williams JA; Korytowsky B; Christensen JG; Lin X; Tursi JM; Lechuga MJ; Van Cutsem E
    J Clin Oncol; 2013 Apr; 31(10):1341-7. PubMed ID: 23358972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
    Graeven U; Arnold D; Reinacher-Schick A; Heuer T; Nusch A; Porschen R; Schmiegel W
    Onkologie; 2007 Apr; 30(4):169-74. PubMed ID: 17396039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
    Aparicio T; Bouché O; Francois E; Retornaz F; Barbier E; Taieb J; Kirscher S; Etienne PL; Faroux R; Khemissa Akouz F; El Hajbi F; Locher C; Rinaldi Y; Lecomte T; Lavau-Denes S; Baconnier M; Oden-Gangloff A; Genet D; Bedenne L; Paillaud E;
    Eur J Cancer; 2018 Jul; 97():16-24. PubMed ID: 29777975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
    Ducreux M; Bouche O; Pignon JP; Mousseau M; Raoul JL; Cassan P; Leduc B; Berger C; Dunant A; Fournet J; Bedenne L;
    Oncology; 2006; 70(3):222-30. PubMed ID: 16816536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
    Kalofonos HP; Papakostas P; Makatsoris T; Papamichael D; Vourli G; Xanthakis I; Aravantinos G; Papadimitriou C; Pentheroudakis G; Varthalitis I; Samelis G; Syrigos KN; Xiros N; Stavropoulos M; Kosmidis P; Christodoulou C; Linardou H; Skondra M; Pectasides D; Economopoulos T; Fountzilas G
    Anticancer Res; 2010 Oct; 30(10):4325-33. PubMed ID: 21036759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.
    Ducreux M; Malka D; Mendiboure J; Etienne PL; Texereau P; Auby D; Rougier P; Gasmi M; Castaing M; Abbas M; Michel P; Gargot D; Azzedine A; Lombard-Bohas C; Geoffroy P; Denis B; Pignon JP; Bedenne L; Bouché O;
    Lancet Oncol; 2011 Oct; 12(11):1032-44. PubMed ID: 21903473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
    Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
    Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
    Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J
    Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
    Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
    Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
    Souglakos J; Pallis A; Kakolyris S; Mavroudis D; Androulakis N; Kouroussis C; Agelaki S; Xenidis N; Milaki G; Georgoulias V
    Oncology; 2005; 69(5):384-90. PubMed ID: 16319509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
    Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ
    Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.